Previous 10 | Next 10 |
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the launch of its R3ACT™ Stabilization System, designed to be a simple solution that allows for multi-stage soft tissue healing following an...
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the first quarter 2022 after market close on Monday, May 9, 2022. The company’s man...
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of Meghan Scanlon to its Board of Directors. Ms. Scanlon has joined the Board’s Compensation and Quality, Technology and Reg...
The following slide deck was published by Paragon 28, Inc. in conjunction with this event. For further details see: Paragon 28 (FNA) Investor Presentation - Slideshow
Vancouver, Kelowna, Delta, BC - March 25, 2022 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Cybersecurity and Cannabis. Today's stocks have been added to our lists of free...
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will be presenting at the Canaccord Genuity Musculoskeletal Conference on March 22 n...
Shares of Paragon 28 (NYSE: FNA) were jumping 13.1% as of 3:20 p.m. ET on Wednesday. The gain came after the medical device maker announced its fourth-quarter results following the market close on Tuesday. Paragon 28 reported net revenue of $42.8 million in the fourth quarter of...
Paragon 28, Inc. (FNA) Q4 2021 Earnings Conference Call March 08, 2022, 04:30 PM ET Company Participants Matt Bacso - Gilmartin Group Albert DaCosta - Chairman and CEO Stephen Deitsch - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Craig Bijou - Bank of ...
Paragon 28 press release (NYSE:FNA): Q4 Net loss $6.2M Revenue of $42.8M (+22.1% Y/Y) beats by $1.36M. For further details see: Paragon 28 reports Q4 results
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and twelve months ended December 31, 2021. 2021 Highligh...
News, Short Squeeze, Breakout and More Instantly...
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2024 after market close on Thursday, August 8, 2024. The Company’s managem...
2024-06-11 17:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-11 02:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...